Sovaldi – Record Breaking Sales More Than Doubled Forecast!

Gilead Sciences Inc has seen record-breaking sales of its new Hepatitis C drug, Sovaldi, with over $2 Billion in the first quarter- the highest EVER for a new medicine. Read more here. (Source: Deena Beasley, Reuters, 4/22/14).

You might also be interested in:

Analyst: Insurance Strategy Pulls Down Drug Prices September 6, 2018
eDossier System to Offer hēRo3 Model Integration November 8, 2018
Study: Physicians Don’t Always See Financial Burden of Cancer July 25, 2018
Report: Insurers Found Solid Footing in Second Quarter August 9, 2018
Novartis Matching Price of Gilead’s CAR-T Therapy May 6, 2018
Health Insurers: Trump Move Could Raise Premiums July 10, 2018
Study: Evidence Supporting Breakthrough Drugs Often Limited July 23, 2018